Our pipeline of new molecular entities is well-positioned to encompass multiple clinical-stage programs in the coming years and reflects our focus and commitment to bring medicines for treating medically-complex and serious conditions to patients with a high unmet medical need, notably in oncology and autoimmune diseases.

Synthon Biopharmaceuticals pipeline 2017

In 2014, we brought our most advanced ADC candidate SYD985 to the clinic for a two-part first-in-human Phase I study.

read more
     Share this page